Hemostatic Agents Market Size, Share, Growth Analysis, By Type (Thrombin Based Hemostats, Gelatin Based Hemostats), By Treatment (Cardiovascular, General Surgery), By End User, By Region - Industry Forecast 2025-2032
세계의 지혈제 시장 규모는 2023년에 73억 8,000만 달러로 평가되며, 2024년 80억 3,000만 달러에서 2032년에는 157억 7,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 8.8%로 성장할 전망입니다.
지혈제 시장은 특히 고령화 사회에서 출혈성 질환과 만성질환의 유병률 증가로 인해 큰 성장이 예상됩니다. 전 세계 외과수술의 급증은 고급 지혈제에 대한 수요를 더욱 증가시키고 있습니다. 세계보건기구(WHO)에 따르면 연간 125만 건 이상의 교통사고가 심각한 출혈의 원인이 되고 있으며, 이는 이러한 약품의 시급한 필요성을 강조하고 있습니다. 또한 로봇 보조 수술과 같은 수술 기법의 발전은 시장 수요를 더욱 증가시킬 것으로 보입니다. 그러나 높은 수술 비용, 불리한 상환 정책, 개발도상국에서의 최근 기술 혁신에 대한 인식 부족 등의 문제가 성장을 저해할 수 있습니다. 이러한 장애물을 극복하는 것은 시장의 잠재력을 최대한 활용하기 위해 매우 중요합니다.
목차
서론
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요의 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
지혈제 시장 규모 : 유형별
- 시장 개요
- 트롬빈 기반 지혈제
- 젤라틴 기반 지혈제
- 콜라겐 기반 지혈제
- 산화 재생 셀룰로오스계 지혈제
- 피브린 실란트
- 기타
지혈제 시장 규모 : 치료별
- 시장 개요
- 심장혈관
- 일반 외과
- 소화기 외과
- 뇌신경외과
- 기타
지혈제 시장 규모 : 최종사용자별
지혈제 시장 규모
- 북미
- 유럽
- 독일
- 스페인
- 프랑스
- 영국
- 이탈리아
- 기타 유럽 지역
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업의 기업 개요
- 회사 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 매출의 전년대비 비교(2022-2024)
주요 기업 개요
- Johnson & Johnson(USA)
- Pfizer Inc.(USA)
- Baxter International Inc.(USA)
- Becton, Dickinson and Company(USA)
- Medtronic plc(Ireland)
- Stryker Corporation(USA)
- Sanofi S.A.(France)
- CSL Limited(Australia)
- Zimmer Biomet Holdings, Inc.(USA)
- Teleflex Incorporated(USA)
- CryoLife, Inc.(USA)
- Integra LifeSciences Holdings Corporation(USA)
- Mallinckrodt Pharmaceuticals(UK)
- B. Braun Melsungen AG(Germany)
- Terumo Corporation(Japan)
- Smith & Nephew plc(UK)
- Haemonetics Corporation(USA)
- Ethicon, Inc.(USA)
- The Medicines Company(USA)
- Anika Therapeutics, Inc.(USA)
결론과 권장사항
KSA
Global Hemostatic Agents Market size was valued at USD 7.38 billion in 2023 and is poised to grow from USD 8.03 billion in 2024 to USD 15.77 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).
The Hemostatic Agents Market is poised for significant growth due to the increasing prevalence of bleeding disorders and chronic diseases, particularly among the aging population. The surge in surgical procedures worldwide further amplifies demand for advanced hemostasis medications. According to the World Health Organization, over 1.25 million road injury incidents annually contribute to severe bleeding, highlighting a pressing need for these agents. Additionally, advancements in surgical techniques, such as robotic-assisted surgeries, will likely drive further market demand. However, challenges such as high surgical costs, unfavorable reimbursement policies, and a lack of awareness about recent technological innovations in developing regions may impede growth. Addressing these hurdles will be crucial for harnessing the market's full potential.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hemostatic Agents Market Segmental Analysis
Global Hemostatic Agents Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Fibrin Sealants and Others. Based on Treatment, the market is segmented into Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery and Others. Based on End User, the market is segmented into Hospitals, Surgery Centers, Nursing Homes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hemostatic Agents Market
The global hemostatic agents market is primarily driven by the increasing frequency of surgical procedures worldwide, which has heightened the need for effective bleeding management during operations. As the number of surgeries rises, so does the incidence of bleeding complications, underscoring the importance of hemostatic products in clinical practice. Significant advancements in medical devices have enhanced the ability to achieve hemostasis, further propelling market growth. Recent data from the National Center for Biotechnology Information (NCBI) indicates that approximately 60-70% of transfused red blood cells are utilized in surgical settings, emphasizing the critical role these agents play in minimizing surgical risks and optimizing patient outcomes.
Restraints in the Global Hemostatic Agents Market
The Global Hemostatic Agents market faces several constraints that hinder its growth. One significant issue is the occurrence of uncontrolled bleeding, which poses a challenge in the widespread adoption of these agents. Although advancements have led to improved management of bleeding during surgeries and reduced infection risks, the high cost of these products remains a barrier to their utilization. Furthermore, specific surgical instruments may only be compatible with certain hemostatic agents, creating additional clinical limitations. Despite technological progress, these constraints continue to restrict the effective application of hemostatic agents in various medical scenarios, hampering their market potential.
Market Trends of the Global Hemostatic Agents Market
The Global Hemostatic Agents market is witnessing a significant trend driven by the escalating need to address hemorrhage, a leading cause of mortality in both military and civilian populations. With over 30% of traumatic deaths resulting from uncontrolled bleeding, the demand for effective hemostatic agents is surging, particularly in emergency and high-stress medical environments. These agents not only stabilize patients by mitigating risks associated with hypothermia, infections, and organ failure but also play a crucial role in trauma care. As awareness of their life-saving potential grows, investment in research and development is likely to further propel market expansion and innovation in hemostatic solutions.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Hemostatic Agents Market Size by Type & CAGR (2025-2032)
- Market Overview
- Thrombin Based Hemostats
- Gelatin Based Hemostats
- Collagen Based Hemostats
- Oxidized Regenerated Cellulose Based Hemostats
- Combination Hemostats
- Fibrin Sealants
- Others
Global Hemostatic Agents Market Size by Treatment & CAGR (2025-2032)
- Market Overview
- Cardiovascular
- General Surgery
- Digestive Surgery
- Neurosurgery
- Others
Global Hemostatic Agents Market Size by End User & CAGR (2025-2032)
- Market Overview
- Hospitals
- Surgery Centers
- Nursing Homes
- Others
Global Hemostatic Agents Market Size & CAGR (2025-2032)
- North America (Type, Treatment, End User)
- Europe (Type, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Treatment, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stryker Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zimmer Biomet Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teleflex Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CryoLife, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Integra LifeSciences Holdings Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mallinckrodt Pharmaceuticals (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- B. Braun Melsungen AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Smith & Nephew plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ethicon, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- The Medicines Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Anika Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
